← All indications
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Subtype terms (7)
More specific conditions that are subtypes of Fibrosis in the MeSH hierarchy.
- Cicatrix
49 drugs (24 approved, 25 experimental)
- Liver Cirrhosis
328 drugs (199 approved, 129 experimental)
- Nephrogenic Fibrosing Dermopathy
5 drugs (4 approved, 1 experimental)
- Peritoneal Fibrosis
- Pulmonary Fibrosis
62 drugs (34 approved, 28 experimental)
- Radiation Fibrosis Syndrome
6 drugs (4 approved, 2 experimental)
- Retroperitoneal Fibrosis
12 drugs (11 approved, 1 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (82)
- propofol
- heparin
- adefovir dipivoxil
- vitamin e
- bacille calmette-guerin
- procaine benzylpenicillin
- cefotaxime
- daclizumab
- empagliflozin
- gadobutrol
- gadoxetate disodium
- tenofovir
- lactulose
- albumin (Human)
- insulin human
- warfarin
- hydrocortisone
- icosapent ethyl
- indocyanine green
- meperidine
- ornithine aspartate
- ledipasvir
- gadopenteate dimeglumine
- nadolol
- norfloxacin
- octreotide
- colchicine
- daclatasvir
- prazosin
- lidocaine
- +52 more
Phase 3 trials (59)
- fluorometholone
- simvastatin
- methacetin
- allopurinol
- corticotropin
- perfluorobutane
- nerandomilast
- ceftazidime
- certolizumab pegol
- Namodenoson
- golimumab
- esmolol
- dornase alfa
- etanercept
- gabapentin
- ethanol
- somatropin
- belapectin
- grapefruit juice
- ritonavir
- rosuvastatin
- human transfer factor
- ketorolac
- daptomycin
- lamivudine
- memantine
- nalmefene
- vitamin c
- adalimumab
- atorvastatin
- +29 more
Phase 2 trials (55)
- fingolimod
- metformin
- maltodextrin
- vitamin d3
- ketoprofen
- azd4831
- ambrisentan
- cc-90001
- tanzisertib
- dark chocolate
- droxidopa
- durvalumab
- glycerol phenylbutyrate
- xenon-129
- idebenone
- emricasan
- autologous cd133+ stem cells
- luspatercept
- ursodeoxycholic acid
- opc-41601
- paraffin oil
- pirfenidone
- pravastatin
- coagulation factor viia (recombinant)
- reparixin
- ruxolitinib
- dasatinib
- tasquinimod
- digoxin
- tremelimumab
- +25 more
Phase 1 trials (24)
Other trials (31)
- melatonin
- cefotiam
- tadalafil
- cyanoacrylate
- fufang biejia ruangan
- whey protein
- leucine
- levocarnitine
- somatostatin
- metoclopramide
- pegvisomant
- praziquantel
- saccharomyces boulardii
- glucose
- urotensin ii
- boceprevir
- thiamine
- zolpidem
- creatine
- high-selenium yeast
- dexmedetomidine
- aspergillus oryzae
- hepatitis b immune globulin (human)
- telaprevir
- erlotinib
- orphenadrine hydrochloride
- simeprevir
- erythromycin
- fructose
- pancreatin
- +1 more
Organizations
Organization Involved with Phase 4 Indications (198)
- Maastricht University
- Icahn School of Medicine at Mount Sinai
- Fifth Hospital of Shijiazhuang City
- University of Lyon
- Cairo University
- Fudan University
- Yanbian University
- Dr. Falk Pharma GmbH
- Gottfried Wilhelm Leibniz Universität Hannover
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Paratek Pharmaceuticals Inc
- Hubei University of Chinese Medicine
- Seoul National University
- University of Toulouse
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
- Good Samaritan Hospital, Cincinnati
- AbbVie
- Vertex
- Universidad Complutense de Madrid
- Roche
- Cystic Fibrosis Foundation Therapeutics
- Zibo City First Hospital
- University of Copenhagen
- Laval University
- Statens Serum Institut
- University of Kentucky
- Badalona Hospital Germans Trias i Pujol
- The Alfred Hospital
- Shandong University of Traditional Chinese Medicine
- Qingdao University
- +168 more
Organization Involved with Phase 3 Indications (167)
- Telethon Kids Institute
- Cystic Fibrosis Federation Australia
- Asahi Kasei Pharma
- University of Adelaide
- Chulalongkorn University
- University of Melbourne
- Janssen Pharmaceutica NV
- KasaConsult bvba
- Eurofins
- Istituto Auxologico Italiano
- Funding for Research in Ophthalmology (FRO)
- University of Montreal
- Telethon Institute for Child Health Research
- Syntara
- Axcan
- Medical University of Gdansk
- University of Alberta
- Federal University of Minas Gerais
- University of Iowa
- University of Lausanne
- Neovii Biotech
- Corus Pharma
- United Therapeutics
- Department of Defense
- National Cancer Institute (NCI)
- University of Rennes
- Otsuka
- TaiwanJ Pharmaceuticals Co., Ltd
- Galectin Therapeutics Inc.
- Isfahan University
- +137 more
Organization Involved with Phase 2 Indications (288)
- Orebro University
- Nitto Denko Corporation
- Centro de Investigación Biomédica en Red (CIBER)
- Baylor University
- Kadmon
- Flatley Discovery Lab LLC
- Beike Biotech
- National Institute for Health Research, United Kingdom
- SCF Pharma
- University of Illinois at Chicago
- Hennepin Healthcare
- Yantai Hospital for Infectious Diseases
- National Center for Global Health and Medicine
- MediciNova
- Shire
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Bharat Biotech International Limited
- United States Navy
- CymaBay Therapeutics, Inc.
- MedImmune
- Corbus Pharmaceuticals Inc.
- Chaitanya Hospital
- Centocor
- Department of Health, United Kingdom
- Ruby Hall Clinic, Pune
- American Health Research
- Ghent University
- Rainbow Baby and Children's Hospital
- Medidata Solutions
- Biosplice Therapeutics
- +258 more
Organization Involved with Phase 1 Indications (61)
- PANGAEA
- Kanazawa University
- Genzyme
- SMSI Institude of Cardiology, Chisinau, Republic of Moldova
- The EMMES Corporation
- NeuPharma, Inc.
- ImmuneWorks
- CSL Behring
- Lakehead University
- Philips
- Aptuit Inc.
- Emphycorp
- University of Arkansas
- Chinese Academy of Sciences
- China Medical University
- Institute of Oncology Dr. Rosell (IOR)
- Lester and Sue Smith Foundation
- American College of Gastroenterology
- SGS Life Sciences
- Medical College of Wisconsin
- Stony Brook University
- Celerion
- Northern Ontario School of Medicine
- Synspira, Inc.
- STRAGEN
- Scientia Clinical Research Limited Sydney
- OpenBiome
- Simbec-Orion
- Clinica Universidad de Navarra
- Nucleus Network Ltd
- +31 more
Organization Involved with Other Experimental Indications (60)
- University of Manitoba
- Canadian Institutes of Health Research (CIHR)
- South Valley University
- Sao Paulo State University
- St. Luke's University Health Network, Bethlehem, PA
- University of South Florida
- University of Caen-Normandie
- GRAPE KING
- Faculdade de Medicina de Botucatu
- Sanford Health
- University of Leeds
- Zagazig University
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Instituto Nacional de Ciencias Medicas y Nutrición
- Loyola University
- Government of Poland
- Kaleido Biosciences
- Xiamen University
- Sorlandet Hospital HF
- European Union
- Paddington Charitable Trust, London
- Taichung Veterans General Hospital
- University of Agder
- Bar Ilan University
- Texas A&M University
- Spanish Clinical Research Network
- Teagasc
- Institut Hospital del Mar d'Investigacions Mèdiques
- Corporal Michael J. Crescenz VA Medical Center
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- +30 more